Repositioning Candidate Details
| Candidate ID: | R0106 |
| Source ID: | DB00388 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Phenylephrine |
| Synonyms: | |
| Molecular Formula: | C9H13NO2 |
| SMILES: | CNC[C@H](O)C1=CC(O)=CC=C1 |
| Structure: |
|
| DrugBank Description: | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil,[L9413] and induce local vasoconstriction.[A187370] The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s.[A187376] Phenylephrine was granted FDA approval in 1939.[L9413] |
| CAS Number: | 59-42-7 |
| Molecular Weight: | 167.205 |
| DrugBank Indication: | Phenylephrine injections are indicated to treat hypotension caused by shock or anesthesia,[L9416, L9410] an ophthalmic formulation is indicated to dilate pupils[L9413] and induce vasoconstriction, an intranasal formulation is used to treat congestion, and a topical formulation is used to treat hemorrhoids.[A187370] Off-label uses include situations that require local blood flow restriction such as the treatment of priapism.[A187370] |
| DrugBank Pharmacology: | Phenylephrine is an alpha-1 adrenergic agonist that raises blood pressure,[L9416,L9410] dilates the pupils,[L9413] and causes local vasoconstriction.[A187370] Ophthalmic formulations of phenylephrine act for 3-8 hours[L9413] while intravenous solutions have an effective half life of 5 minutes and an elimination half life of 2.5 hours.[A187379,L9416] Patients taking ophthalmic formulations of phenylephrine should be counselled about the risk of arrhythmia, hypertension, and rebound miosis.[L9413] Patients taking an intravenous formulation should be counselled regarding the risk of bradycardia, allergic reactions, extravasation causing necrosis or tissue sloughing, and the concomitant use of oxytocic drugs.[L9416,L9410] |
| DrugBank MoA: | Phenylephrine is an alpha-1 adrenergic agonist that mediates vasoconstriction[A187370] and mydriasis[L9413] depending on the route and location of administration. Systemic exposure to phenylephrine also leads to agonism of alpha-1 adrenergic receptors, raising systolic and diastolic pressure as well as peripheral vascular resistance.[L9416,L9410] Increased blood pressure stimulates the vagus nerve, causing reflex bradycardia.[L9416,L9410] |
| Targets: | Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name | |
|---|---|---|---|---|---|---|---|
| T03 | Angiotensin-converting enzyme | ACE | INHIBITOR | Target is a single protein chain | P12821 | ACE_HUMAN | Details |
| T06 | Sulfonylurea receptor 1 | ABCC8 | Target is a single protein chain | Q09428 | ABCC8_HUMAN | Details | |
| T47 | Sialin | SLC17A5 | Target is a single protein chain | Q9NRA2 | SLC17A5_HUMAN | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |